A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism — PRIORITY  

Pancreatic Cancer Clinical Trial

Official title: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY

Status Recruiting

Clinical Trial Summary

This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper gastrointestinal, hepatobiliary, or pancreatic cancer, based on a group sequential design. Enrolled patients will be randomized in a 1:1 ratio. Patients will be stratified by performance status, type of cancer, chemotherapy and medical centers.

Clinical Trial Description

This randomized II clinical trial will enrol patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer who have venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Patients will be randomized in a 1:1 ratio and stratified by performance status, type of cancer and medical centers. The enrolled patients will receive either subcutaneous dalteparin or DOAC(rivaroxaban, apixavan) according to randomization until the end of planned treatment schedules (six months), recurrence of VTE, clinical relevant bleeding, major bleeding, death or discontinuation of study treatment for any other reason (e.g. withdrawal of consent or discretion of the investigator). The primary end-point is the rate of clinical relevant bleeding event as defined as overt bleeding which was associated with medical intervention. In addition to time to clinical relevant bleeding event, time to event of major bleeding, total bleeding including minor event, time to recurrent VTE, overall bleeding rate and overall VTE recurrent rate will be analyzed to compare safety and efficacy of both anticoagulants. The final analysis will be conducted when the last enrolled patient has an event or has completed as least six months follow up in the study. Patients without bleeding and recurrent VTE events at data cut-off are censored at the last date the patient is known to be free of events.

Planned interim analysis will be conducted in the intentions to treatment analysis set. The interim analysis for the randomized portion of the study will be performed when at least 40% of estimated bleeding events have been observed. The purpose of interim analysis is for early stopping of the study for safety. This study will use a Data Monitoring Committee. ;

Related Conditions & MeSH terms

• Ampulla of Vater Cancer
• Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
• Cancer-associated Thrombosis
• Cholangiocarcinoma
• Duodenal Cancer
• Duodenal Neoplasms
• Esophageal Cancer
• Esophagogastric Junction Cancer
• Gallbladder Neoplasms
• Gastrointestinal Stromal Tumors
• Hepatocellular Carcinoma
• Malignant Gastrointestinal Stromal Tumor
• Pancreatic Cancer
• Pancreatic Neoplasms
• Stomach Cancer
• Stomach Neoplasms
• Thromboembolism
• Thrombosis
• Venous Thromboembolism

• NCT number: NCT03139487
• Study type: Interventional
• Source: Asan Medical Center
• Contact: Sook Ryun Park, M.D., Ph.D.
• Phone: +82-2-3010-3210
• Email: srpark@amc.seoul.kr
• Status: Recruiting
• Phase: Phase 2
• Start date: August 7, 2017
• Completion date: September 30, 2021